Liver biopsy can provide direct histologic assessment of liver injury due to HCV but cannot be used to diagnose HCV infection.

**Hepatocellular Carcinoma Screening**

HCC complicates cirrhosis secondary to HCV. It is estimated that HCC occurs after the development of cirrhosis at a rate varying from 0 to 3 percent per year. Alpha-fetoprotein (AFP) and ultrasound every 6 months were used in a single study of patients with cirrhosis secondary to HCV. Identification of HCC was not significantly increased in the screened population. The value of screening for AFP is uncertain because there are no available data to demonstrate the clinical impact of this screening on the management of HCC or associated mortality. Studies of the performance characteristics of AFP and hepatic ultrasound show that AFP has a poor sensitivity and a high rate of false-positive reactions. Hepatic ultrasound is more sensitive than AFP testing but is also more expensive, and it can lead to invasive and unnecessary evaluations of lesions (e.g., regenerative nodules, hemangiomas, hepatic cysts) that are not HCC. However, such routine AFP or imaging screening should not be performed in patients with HCV in the absence of cirrhosis because HCC is so rare in this group.

**What is the most effective therapy for hepatitis C?**

Currently the best indicator of effective treatment is an SVR, defined by the absence of detectable HCV RNA in the serum as shown by a qualitative HCV RNA assay with lower limit of detection of 50 IU/mL or less at 24 weeks after the end of treatment.

**Treatment of Naive Patients**

Three large pivotal trials have examined the efficacy of pegylated interferon plus ribavirin in the treatment of chronic HCV infection. Overall, pegylated interferon plus ribavirin was more effective than standard interferon-ribavirin combination or pegylated interferon alone. Among patients with genotypes 2 or 3, SVRs with standard interferon and ribavirin were comparable to those with pegylated interferon and ribavirin, and thus standard interferon and ribavirin could be used in treating patients with these genotypes.

In a recent study, a 24-week course of pegylated interferon and ribavirin was found to be as effective as a 48-week course in patients with genotypes 2 and 3 (SVR rates of 73 to 78 percent), but not in patients with genotype 1 (SVR rates of 41% with 24 weeks and 51% with 48 weeks). Similarly, a reduced ribavirin dosage of 800 mg daily appeared to be adequate for patients with genotypes 2 and 3, but the higher, standard dosage of 1000 to 1200 mg daily yielded better response rates in patients with genotype 1. Thus, 24 weeks of treatment and an 800 mg dose of ribavirin appear to be sufficient for persons with genotypes 2 and 3, while patients with genotype 1 need 48 weeks of treatment and standard doses of ribavirin.

Early viral response (EVR) defined, as a minimum 2-log decrease in viral load during the first 12 weeks of treatment, is predictive of SVR and should be a routine part of monitoring patients with genotype 1. Patients who fail to achieve an EVR at week 12 of treatment have only a small chance of achieving an SVR even if therapy is continued for...
a full year. Treatment need not be extended beyond 12 weeks in these patients. Although an SVR is difficult to correlate with improved survival because of the necessity for long-term follow-up, the absence of detectable serum HCV RNA has been associated with resolution of liver injury, reduction in hepatic fibrosis, and a low likelihood of a relapse of the HCV infection. Additionally, in two large but uncontrolled long-term follow-up studies from Japan, SVR after interferon treatment was associated with a lower risk of HCC. Conversely, one observational Italian study with long-term follow-up found no difference in development of HCC between those with and without interferon treatment.

**Re-treatment of Patients**

Studies are currently being conducted with pegylated interferon and ribavirin therapy in patients who relapsed after interferon monotherapy or standard interferon and ribavirin therapy.

Failure to respond to optimal therapy with pegylated interferon and ribavirin presents a significant problem, particularly in the presence of advanced fibrosis or cirrhosis. Currently, several large-scale, multicenter U.S. trials are evaluating the role of maintenance therapy with pegylated interferon alone in preventing further progression of cirrhosis, clinical decompensation, or development of HCC. Until the results of these studies are available, the role of long-term, continuous therapy with pegylated interferon (or ribavirin or both) for nonresponders should be considered experimental.

**Adherence**

Patient adherence is critical to the success of treatment of HCV. Physicians should discuss the importance of adherence with patients before embarking on therapy and regularly assess and take steps to help their patients maximize their adherence. Such measures include management of side effects, depression, and substance abuse.

**Side Effects of Treatment**

In registration trials of pegylated interferon and ribavirin, significant side effects resulted in discontinuation of treatment in approximately 10 to 14 percent of patients. Major side effects of combination therapy include influenza-like symptoms, hematologic abnormalities, and neuropsychiatric symptoms. The education of patients, their family members, and caregivers about side effects and their prospective management is an integral aspect of treatment. Frequent monitoring of neuropsychiatric side effects, cytopenia, and adherence to HCV therapy is necessary. Psychological conditions, particularly depression, are common among persons with HCV and are frequent side effects of interferon. The patient's mental health status should be assessed before beginning antiviral therapy and monitored regularly during therapy. It is not known if the use of hematopoietic growth factors will enhance the likelihood of SVR. Thus, the benefits of such treatment need to be proven prospectively before it can be recommended.
Which patients with hepatitis C should be treated?

All patients with chronic HCV are potential candidates for antiviral therapy. Treatment is recommended for patients with an increased risk of developing cirrhosis. These patients are characterized by:

- Detectable HCV RNA levels higher than 50 IU/mL,
- A liver biopsy with findings of portal or bridging fibrosis, and at least Moderate inflammation and necrosis, and
- Persistently elevated ALT values.

Because a large number of HCV-infected persons in the United States are incarcerated, programs should be implemented to prevent, diagnose, and treat HCV infection in these individuals. Patients with chronic HCV should be vaccinated against hepatitis A, and seronegative persons with risk factors for hepatitis B virus (HBV) should be vaccinated against HBV.

Normal ALT Levels

Approximately 30 percent of patients with chronic HCV infection have normal ALT levels, and another 40 percent have ALT levels less than two times the upper limit of normal (70% have <2x the upper limit). Although most of these patients have mild disease, histologically, some may progress to advanced fibrosis and cirrhosis. Experts differ on whether to biopsy and treat these patients.

Studies of pegylated interferon with ribavirin have not been completed in patients with normal ALT levels.

Mild Liver Disease

Progression to cirrhosis is likely to be slow in patients who have persistent ALT elevations but no fibrosis and minimal necroinflammatory changes. These patients may not need treatment and should be monitored periodically.

Recurrence After Transplantation

Hepatitis C frequently recurs following liver transplantation, and disease progression is accelerated compared with immunocompetent patients with HCV disease. Once cirrhosis develops in the allograft, the risk of complications is high. While recurrence of HCV replication is almost universal after liver transplantation, the severity of the recurrence of HCV after transplant correlates with the degree of immunosuppression in the posttransplantation period. Treatment of HCV recurrence after liver transplantation should be considered experimental and carried out in the context of clinical trials.
Active Injection Drug Users

Recent, albeit limited, experience has demonstrated the feasibility and effectiveness of treating chronic HCV in people who use illicit injection drugs, known as injection drug users (IDUs). Treatment for drug and alcohol abuse should be made available to all patients who want and need it. However, few data are available on HCV treatment in active IDUs who are not in drug treatment programs. Thus, it is recommended that treatment of active injection drug use be considered on a case-by-case basis, and that active injection drug use in and of itself not be used to exclude such patients from antiviral therapy.

HIV Co-infection

Although there are no HCV therapies specifically approved for patients co-infected with HIV, these patients should be considered for treatment.

Alcohol and HCV

Alcohol is an important cofactor in the progression of HCV liver disease to cirrhosis and HCC. A history of alcohol abuse is not a contraindication to therapy; however, continued alcohol use during therapy adversely affects response to treatment, and alcohol abstinence is strongly recommended before and during antiviral therapy. Heavy alcohol consumption of >80 g/day seriously compromises HCV treatment. Furthermore, safe levels of alcohol consumption are still unclear, and even moderate levels of consumption may accelerate disease progression in some patients.

Recommendations to be made to patients to prevent transmission of hepatitis C

The large reservoir of individuals infected with HCV provides a source of transmission to others at risk. Direct percutaneous exposure is the most efficient method for transmitting HCV, and injection drug use accounts for more than two-thirds of all new infections in the United States. Methadone treatment programs, needle and syringe exchange programs, and comprehensive risk-modifying educational programs have been shown to be effective in preventing HIV transmission and are likely to be useful for decreasing HCV transmission. Ensuring access to sterile syringes through physician prescription and pharmacy sales of syringes to IDUs can also be helpful. IDUs should be educated about the importance of hand washing before and after giving injections, not using the others' injection equipment, and avoiding any contact with blood from other persons. HCV prevention education should be a high priority in correctional settings.

In the United States, the estimated seroprevalence of HCV is 2 to 3 percent among partners of HCV-infected persons who are in long-term monogamous relationships and is 4 to 6 percent among persons with multiple sex partners, sex workers, and men who have sex with men (those at risk for sexually transmitted diseases). One study found the risk of HCV infection to be threefold higher for female than male sexual partners. Because of the low risk of HCV transmission, monogamous couples do not need to use barrier protection (condoms) although they should be advised that condoms may reduce the risk of transmission. There is no evidence that kissing, hugging, sneezing, coughing, food,
water, sharing eating utensils or drinking glasses, casual contact, or other contact without exposure to blood is associated with HCV transmission for correctional staff.

Body piercing and tattooing are other potential sources of transmission if contaminated equipment or supplies are used. However, transmission through these activities is rare and confounded by other risk factors.

RECOMMENDATIONS

➢ Educate the American public on the transmission of HCV in order to better identify affected individuals and to institute preventive measures.

➢ Promote the establishment of screening tests for all groups at high risk of HCV infection, including IDUs and incarcerated individuals.

➢ Institute measures to reduce transmission of HCV among IDUs, including providing access to sterile syringes through needle exchange, physician prescription, and pharmacy sales; and expanding the Nation's capacity to provide treatment for substance abuse. Physicians and pharmacists should be educated to recognize that providing IDUs with access to sterile syringes and education in safe injection practices may be lifesaving.

➢ Encourage a comprehensive approach to promote the collaboration among health professionals concerned with management of addiction. Primary care physicians, and specialists should be involved in various aspects of HCV management - to deal with the complex societal, medical, and psychiatric issues of IDUs afflicted by the disease.
Summary
National Institutes of Health
Consensus Development Conference Statement
Management of Hepatitis C
Final Statement

*The complete 44-page document can be found at http://www.nih.gov/.*

The NIH Consensus Development Conference on Management of Hepatitis C: 2002 was held June 10 - 12, 2002. The final statement was published September 12, 2002. The “Final Statement” contains the following disclaimers:

1. “This statement is not a policy statement of the NIH or the Federal Government”
   and
2. “Thus, it provides a “snapshot in time” of the state of knowledge”.

The Virus

The lack of a vigorous T-lymphocyte response and the high propensity of the virus to mutate appear to promote a high rate of chronic infection. The extensive genetic heterogeneity of Hepatitis C virus (HCV) has important diagnostic and clinical implications, perhaps explaining difficulties in vaccine development and the lack of response to therapy. Genotype 1 accounts for 70 to 75 percent of all HCV infections in the United States and is associated with a lower rate of response to treatment.

HCV replicates preferentially in hepatocytes but is not directly cytopathic. During chronic infection, HCV RNA reaches high levels, generally ranging from $10^5$ to $10^7$ international units (IU)/mL, but the levels can fluctuate widely. However, within the same individual, RNA levels are usually relatively stable.

Epidemiology

Although difficult to assess accurately, the incidence of HCV infections declined sharply in the late 1980s. However, the estimated prevalence of HCV in the U.S. is at least 1.8 percent of the population and a fourfold increase in the number of adults diagnosed with chronic HCV infection is projected from 1990 to 2015. Currently, persons aged 40 to 59 years have the highest prevalence of HCV infection, and in this age group, the prevalence is highest in African Americans (6.1%). High HCV seroprevalence rates (from 15-50 percent) have occurred in specific subpopulation, such as homeless, incarcerated persons, injection drug users, and persons with hemophilia who were treated with clotting factors before 1992. The highest seroprevalence rates (70 to more than 90 percent) have been reported in the last of these two groups.

Chronic Infection
Persistence of HCV infection is diagnosed by the detection of HCV RNA in the blood for at least 6 months. In general, prospective studies have shown that 60 to 85 percent of HCV-infected persons develop chronic infection.

The most important sequelae of chronic HCV infection are progressive liver fibrosis leading to cirrhosis, end-stage liver disease, and Hepatocellular Carcinoma (HCC). Estimates of the proportion of chronically infected persons who develop cirrhosis 20 years after initial infection vary widely from 2 to 4 percent in studies of children and young women to as high as 20 to 30 percent in middle-aged transfused subjects. The actual risk is likely intermediate between these two ranges, on the order of 10 to 15 percent. There is little evidence that virologic factors, including viral load, viral genotype, and quasi-species diversity significantly affect the risk of progression of liver disease. However, many host factors increase this risk, including:

- Older age at time of infection,
- Male gender,
- Immunosuppression such as that associated with HIV infection, and
- Concurrent chronic hepatitis B infection.
- Higher levels of alcohol use play an important role in promoting the development of progressive liver disease, with strong evidence for the detrimental effects of 30 g/day in men (~ equivalent to 2 beers, 2 glasses of wine, or 2 mixed drinks) and 20 g/day in women.
- Conversely, individuals infected at a younger age have little or no disease progression over several decades.

Hepatocellular Carcinoma

HCC rarely occurs in the absence of cirrhosis or advanced fibrosis. Risk factors for HCC in persons with chronic HCV infection are largely the same as those for the development of decompensated cirrhosis. Some but not all studies suggest that treatment with interferon and ribavirin may reduce the risk of developing HCC in HCV patients with cirrhosis, but more data are needed.

HCV Serologic Assays

Enzyme immunoassay (EIA) tests are reproducible, inexpensive, and FDA-approved for use in the diagnosis of HCV infection. The very high sensitivity (low rate of false negative) and specificity (low rate of false positive) of the version 3 (third-generation) EIA (sensitivity of greater than 99 percent, specificity of 99 percent in immunocompetent patients) obviate the need for a confirmatory immunoblot assay in the diagnosis of individual patients with clinical liver disease, particularly those with risk factors for HCV infection.

Qualitative HCV RNA Assays

Chronic HCV infection in a patient with a positive EIA test should be confirmed by a qualitative HCV RNA assay with a lower limit of detection of 50 IU/mL or less (approximately 100 viral genes/mL). A single positive qualitative assay for HCV RNA
confirms active HCV replication, but a single negative assay does not exclude viremia and may reflect only a transient decline in viral level below the level of detection of the assay.

Until future studies determine whether the sustained virological response (SVR) will be sustained over the long term following successful antiviral treatment, periodic measurements of HCV RNA may need to be performed.

**Quantitative HCV RNA Assays**

Testing for HCV RNA level (or viral load) with a quantitative assay provides accurate information on HCV viral levels. Significant variability exists between available assays. The clinical utility of serial HCV viral levels in a patient is predicated on continued use of the same specific quantitative assay that was used in the initial determination of the viral level. While there is little correlation between disease severity or disease progression with the absolute level of HCV RNA, quantitative determination of the HCV level provides important information on the likelihood of response to treatment in patients undergoing antiviral therapy.

**ALT**

Testing for serum ALT levels is the most inexpensive and noninvasive, but relatively insensitive, means of assessing disease activity. Serial determinations of ALT levels over time may provide a better means of assessing liver injury, but the accuracy of this approach has not been well documented. Patients who initially have a normal ALT level should undergo serial measurements over several months to confirm the persistence of normal ALT levels. Although loss or reduction in HCV RNA is the primary indicator of response to antiviral therapy, the resolution of elevated ALT levels with antiviral therapy appears to be an important indicator of disease response.

**Noninvasive Tests of Fibrosis**

No single test or panel of serologic markers can provide an accurate assessment of intermediate stages of hepatic fibrosis. Similarly, quantitative tests of liver function and radiologic imaging of the liver are sensitive for diagnosing advanced cirrhosis but are not useful in assessing hepatic fibrosis and early cirrhosis.

**Liver Biopsy**

Liver biopsy provides a unique source of information on fibrosis and assessment of histology. The information obtained on liver biopsy allows affected individuals to make more informed choices about the initiation or postponement of antiviral treatment. Thus, the liver biopsy is a useful part of the informed consent process.

In general, a baseline assessment of liver histology offers a valuable standard for subsequent comparisons. However, the appropriate interval for subsequent evaluations is yet to be determined.
Liver biopsy can provide direct histologic assessment of liver injury due to HCV but cannot be used to diagnose HCV infection.

**Hepatocellular Carcinoma Screening**

HCC complicates cirrhosis secondary to HCV. It is estimated that HCC occurs after the development of cirrhosis at a rate varying from 0 to 3 percent per year. Alpha-fetoprotein (AFP) and ultrasound every 6 months were used in a single study of patients with cirrhosis secondary to HCV. Identification of HCC was not significantly increased in the screened population. The value of screening for AFP is uncertain because there are no available data to demonstrate the clinical impact of this screening on the management of HCC or associated mortality. Studies of the performance characteristics of AFP and hepatic ultrasound show that AFP has a poor sensitivity and a high rate of false-positive reactions. Hepatic ultrasound is more sensitive than AFP testing but is also more expensive, and it can lead to invasive and unnecessary evaluations of lesions (e.g., regenerative nodules, hemangiomas, hepatic cysts) that are not HCC. However, such routine AFP or imaging screening should not be performed in patients with HCV in the absence of cirrhosis because HCC is so rare in this group.

**What is the most effective therapy for hepatitis C?**

Currently the best indicator of effective treatment is an SVR, defined by the absence of detectable HCV RNA in the serum as shown by a qualitative HCV RNA assay with lower limit of detection of 50 IU/mL or less at 24 weeks after the end of treatment.

**Treatment of Naive Patients**

Three large pivotal trials have examined the efficacy of pegylated interferon plus ribavirin in the treatment of chronic HCV infection. Overall, pegylated interferon plus ribavirin was more effective than standard interferon-ribavirin combination or pegylated interferon alone. Among patients with genotypes 2 or 3, SVRs with standard interferon and ribavirin were comparable to those with pegylated interferon and ribavirin, and thus standard interferon and ribavirin could be used in treating patients with these genotypes.

In a recent study, a 24-week course of pegylated interferon and ribavirin was found to be as effective as a 48-week course in patients with genotypes 2 and 3 (SVR rates of 73 to 78 percent), but not in patients with genotype 1 (SVR rates of 41% with 24 weeks and 51% with 48 weeks). Similarly, a reduced ribavirin dosage of 800 mg daily appeared to be adequate for patients with genotypes 2 and 3, but the higher, standard dosage of 1000 to 1200 mg daily yielded better response rates in patients with genotype 1. Thus, 24 weeks of treatment and an 800 mg dose of ribavirin appear to be sufficient for persons with genotypes 2 and 3, while patients with genotype 1 need 48 weeks of treatment and standard doses of ribavirin.

Early viral response (EVR) defined, as a minimum 2-log decrease in viral load during the first 12 weeks of treatment, is predictive of SVR and should be a routine part of monitoring patients with genotype 1. Patients who fail to achieve an EVR at week 12 of treatment have only a small chance of achieving an SVR even if therapy is continued for
a full year. Treatment need not be extended beyond 12 weeks in these patients. Although an SVR is difficult to correlate with improved survival because of the necessity for long-term follow-up, the absence of detectable serum HCV RNA has been associated with resolution of liver injury, reduction in hepatic fibrosis, and a low likelihood of a relapse of the HCV infection. Additionally, in two large but uncontrolled long-term follow-up studies from Japan, SVR after interferon treatment was associated with a lower risk of HCC. Conversely, one observational Italian study with long-term follow-up found no difference in development of HCC between those with and without interferon treatment.

Re-treatment of Patients

Studies are currently being conducted with pegylated interferon and ribavirin therapy in patients who relapsed after interferon monotherapy or standard interferon and ribavirin therapy.

Failure to respond to optimal therapy with pegylated interferon and ribavirin presents a significant problem, particularly in the presence of advanced fibrosis or cirrhosis. Currently, several large-scale, multicenter U.S. trials are evaluating the role of maintenance therapy with pegylated interferon alone in preventing further progression of cirrhosis, clinical decompensation, or development of HCC. Until the results of these studies are available, the role of long-term, continuous therapy with pegylated interferon (or ribavirin or both) for nonresponders should be considered experimental.

Adherence

Patient adherence is critical to the success of treatment of HCV. Physicians should discuss the importance of adherence with patients before embarking on therapy and regularly assess and take steps to help their patients maximize their adherence. Such measures include management of side effects, depression, and substance abuse.

Side Effects of Treatment

In registration trials of pegylated interferon and ribavirin, significant side effects resulted in discontinuation of treatment in approximately 10 to 14 percent of patients. Major side effects of combination therapy include influenza-like symptoms, hematologic abnormalities, and neuropsychiatric symptoms. The education of patients, their family members, and caregivers about side effects and their prospective management is an integral aspect of treatment. Frequent monitoring of neuropsychiatric side effects, cytopenia, and adherence to HCV therapy is necessary. Psychological conditions, particularly depression, are common among persons with HCV and are frequent side effects of interferon. The patient's mental health status should be assessed before beginning antiviral therapy and monitored regularly during therapy.

It is not known if the use of hematopoietic growth factors will enhance the likelihood of SVR. Thus, the benefits of such treatment need to be proven prospectively before it can be recommended.
Which patients with hepatitis C should be treated?

All patients with chronic HCV are potential candidates for antiviral therapy. Treatment is recommended for patients with an increased risk of developing cirrhosis. These patients are characterized by:

- Detectable HCV RNA levels higher than 50 IU/mL,
- A liver biopsy with findings of portal or bridging fibrosis, and at least Moderate inflammation and necrosis, and
- Persistently elevated ALT values.

Because a large number of HCV-infected persons in the United States are incarcerated, programs should be implemented to prevent, diagnose, and treat HCV infection in these individuals. Patients with chronic HCV should be vaccinated against hepatitis A, and seronegative persons with risk factors for hepatitis B virus (HBV) should be vaccinated against HBV.

Normal ALT Levels

Approximately 30 percent of patients with chronic HCV infection have normal ALT levels, and another 40 percent have ALT levels less than two times the upper limit of normal (70% have <2x the upper limit). Although most of these patients have mild disease, histologically, some may progress to advanced fibrosis and cirrhosis. Experts differ on whether to biopsy and treat these patients.

Studies of pegylated interferon with ribavirin have not been completed in patients with normal ALT levels.

Mild Liver Disease

Progression to cirrhosis is likely to be slow in patients who have persistent ALT elevations but no fibrosis and minimal necroinflammatory changes. These patients may not need treatment and should be monitored periodically.

Recurrence After Transplantation

Hepatitis C frequently recurs following liver transplantation, and disease progression is accelerated compared with immunocompetent patients with HCV disease. Once cirrhosis develops in the allograft, the risk of complications is high. While recurrence of HCV replication is almost universal after liver transplantation, the severity of the recurrence of HCV after transplant correlates with the degree of immunosuppression in the posttransplantation period. Treatment of HCV recurrence after liver transplantation should be considered experimental and carried out in the context of clinical trials.

Hepatitis C Position Statement – Alabama Department of Corrections
Summary of NIH Statement

Page 6 of 8
February, 2003
Active Injection Drug Users

Recent, albeit limited, experience has demonstrated the feasibility and effectiveness of treating chronic HCV in people who use illicit injection drugs, known as injection drug users (IDUs). Treatment for drug and alcohol abuse should be made available to all patients who want and need it. However, few data are available on HCV treatment in active IDUs who are not in drug treatment programs. Thus, it is recommended that treatment of active injection drug use be considered on a case-by-case basis, and that active injection drug use in and of itself not be used to exclude such patients from antiviral therapy.

HIV Co-infection

Although there are no HCV therapies specifically approved for patients co-infected with HIV, these patients should be considered for treatment.

Alcohol and HCV

Alcohol is an important cofactor in the progression of HCV liver disease to cirrhosis and HCC. A history of alcohol abuse is not a contraindication to therapy; however, continued alcohol use during therapy adversely affects response to treatment, and alcohol abstinence is strongly recommended before and during antiviral therapy. Heavy alcohol consumption of >80 g/day seriously compromises HCV treatment. Furthermore, safe levels of alcohol consumption are still unclear, and even moderate levels of consumption may accelerate disease progression in some patients.

Recommendations to be made to patients to prevent transmission of hepatitis C

The large reservoir of individuals infected with HCV provides a source of transmission to others at risk. Direct percutaneous exposure is the most efficient method for transmitting HCV, and injection drug use accounts for more than two-thirds of all new infections in the United States. Methadone treatment programs, needle and syringe exchange programs, and comprehensive risk-modifying educational programs have been shown to be effective in preventing HIV transmission and are likely to be useful for decreasing HCV transmission. Ensuring access to sterile syringes through physician prescription and pharmacy sales of syringes to IDUs can also be helpful. IDUs should be educated about the importance of hand washing before and after giving injections, not using the others’ injection equipment, and avoiding any contact with blood from other persons. HCV prevention education should be a high priority in correctional settings.

In the United States, the estimated seroprevalence of HCV is 2 to 3 percent among partners of HCV-infected persons who are in long-term monogamous relationships and is 4 to 6 percent among persons with multiple sex partners, sex workers, and men who have sex with men (those at risk for sexually transmitted diseases). One study found the risk of HCV infection to be threefold higher for female than male sexual partners. Because of the low risk of HCV transmission, monogamous couples do not need to use barrier protection (condoms) although they should be advised that condoms may reduce the risk of transmission. There is no evidence that kissing, hugging, sneezing, coughing, food,
water, sharing eating utensils or drinking glasses, casual contact, or other contact without exposure to blood is associated with HCV transmission for correctional staff.

Body piercing and tattooing are other potential sources of transmission if contaminated equipment or supplies are used. However, transmission through these activities is rare and confounded by other risk factors.

RECOMMENDATIONS

➢ Educate the American public on the transmission of HCV in order to better identify affected individuals and to institute preventive measures.

➢ Promote the establishment of screening tests for all groups at high risk of HCV infection, including IDUs and incarcerated individuals.

➢ Institute measures to reduce transmission of HCV among IDUs, including providing access to sterile syringes through needle exchange, physician prescription, and pharmacy sales; and expanding the Nation's capacity to provide treatment for substance abuse. Physicians and pharmacists should be educated to recognize that providing IDUs with access to sterile syringes and education in safe injection practices may be lifesaving.

➢ Encourage a comprehensive approach to promote the collaboration among health professionals concerned with management of addiction. Primary care physicians, and specialists should be involved in various aspects of HCV management - to deal with the complex societal, medical, and psychiatric issues of IDUs afflicted by the disease.